R&D News | pharmaphorum

News

EULAR 26 hears of treatment advances in lupus

Three trials of potentially first-in-class therapies for J&J, UCB/Biogen, and Merck KGaA at EULAR have offered hope of new targeted drugs for lupus.

News

£600m funding call opens for UK biomedical research centres

£600m in funding is being allocated for an expansion in the network of biomedical research centres, a pillar of the UK's life sciences strategy.

News

Analogue alarm clock with three piles of gold coins and plant shoot growing from them

NewLimit raises $435m for liver trials, and other financings

Longevity biotech NewLimit's $435m Series C heads this week's round-up of biotech venture capital financings.

News

White jigsaw pieces on a yellow background

Lilly strikes $1.9bn kidney disease alliance with Ascidian

In its third big licensing deal of the week, Eli Lilly has tapped RNA-editing specialist Ascidian for kidney disease therapies in a $1.9bn alliance.

News

ASCO26: Celcuity punished as trial disappoints investors

Celcuity is still confident it has a winner with its breast cancer treatment, gedatolisib, but investors seem less convinced by new VIKTORIA-1 data.

News

ASCO26: In vivo CAR-Ts in the spotlight

Data at ASCO on in vivo CAR-Ts from Kelonia and Legend add to the excitement about the emerging therapy class in both blood cancers and solid tumours.

EULAR 26 hears of treatment advances in lupus

£600m funding call opens for UK biomedical research centres

NewLimit raises $435m for liver trials, and other financings

Lilly strikes $1.9bn kidney disease alliance with Ascidian

ASCO26: Celcuity punished as trial disappoints investors

ASCO26: In vivo CAR-Ts in the spotlight

FDA issues warning letters to five unapproved GLP-1 websites

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks